CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression - PubMed (original) (raw)
. 1999 May 15;59(10):2302-6.
Affiliations
- PMID: 10344733
CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression
C A Eads et al. Cancer Res. 1999.
Erratum in
- Cancer Res 1999 Nov 15;59(22):5860
Abstract
The molecular basis of aberrant hypermethylation of CpG islands observed in a subset of human colorectal tumors is unknown. One potential mechanism is the up-regulation of DNA (cytosine-5)-methyltransferases. Recently, two new mammalian DNA methyltransferase genes have been identified, which are referred to as DNMT3A and DNMT3B. The encoded proteins differ from the predominant mammalian DNA methyltransferase DNMT1 in that they have a substantially higher ratio of de novo to maintenance methyltransferase activity. We have used a highly quantitative 5' nuclease fluorogenic reverse transcription-PCR method (TaqMan) to analyze the expression of all three DNA methyltransferase genes in 25 individual colorectal adenocarcinoma specimens and matched normal mucosa samples. In addition, we examined the methylation patterns of four CpG islands [APC, ESR1 (estrogen receptor), CDKN2A (p16), and MLH1] to determine whether individual tumors show a positive correlation between the level of DNA methyltransferase expression and the frequency of CpG island hypermethylation. All three methyltransferases appear to be up-regulated in tumors when RNA levels are normalized using either ACTB (beta-actin) or POLR2A (RNA pol II large subunit), but not when RNA levels are normalized with proliferation-associated genes, such as H4F2 (histone H4) or PCNA. The frequency or extent of CpG island hypermethylation in individual tumors did not correlate with the expression of any of the three DNA methyltransferases. Our results suggest that deregulation of DNA methyltransferase gene expression does not play a role in establishing tumor-specific abnormal DNA methylation patterns in human colorectal cancer.
Similar articles
- DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells.
Ahluwalia A, Hurteau JA, Bigsby RM, Nephew KP. Ahluwalia A, et al. Gynecol Oncol. 2001 Aug;82(2):299-304. doi: 10.1006/gyno.2001.6284. Gynecol Oncol. 2001. PMID: 11531283 - Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer.
de Vogel S, Wouters KA, Gottschalk RW, van Schooten FJ, de Goeij AF, de Bruïne AP, Goldbohm RA, van den Brandt PA, Weijenberg MP, van Engeland M. de Vogel S, et al. Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3086-96. doi: 10.1158/1055-9965.EPI-09-0289. Epub 2009 Oct 20. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19843671 Clinical Trial. - Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers.
Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, Sasako M, Kitano S, Hirohashi S. Etoh T, et al. Am J Pathol. 2004 Feb;164(2):689-99. doi: 10.1016/S0002-9440(10)63156-2. Am J Pathol. 2004. PMID: 14742272 Free PMC article. - DNA methylation changes in leukaemia.
Melki JR, Clark SJ. Melki JR, et al. Semin Cancer Biol. 2002 Oct;12(5):347-57. doi: 10.1016/s1044-579x(02)00055-x. Semin Cancer Biol. 2002. PMID: 12191634 Review. - De novo methyltransferases: Potential players in diseases and new directions for targeted therapy.
Saravanaraman P, Selvam M, Ashok C, Srijyothi L, Baluchamy S. Saravanaraman P, et al. Biochimie. 2020 Sep;176:85-102. doi: 10.1016/j.biochi.2020.07.004. Epub 2020 Jul 11. Biochimie. 2020. PMID: 32659446 Review.
Cited by
- DNMT3B Expression Might Contribute to Abnormal Methylation of RASSF1A in Lager Colorectal Adenomatous Polyps.
Meng X, Liu N, Jia Y, Gong K, Zhang J, Zhang W, Shao G, Dang T. Meng X, et al. Gastroenterol Res Pract. 2020 Oct 1;2020:1798729. doi: 10.1155/2020/1798729. eCollection 2020. Gastroenterol Res Pract. 2020. PMID: 33061956 Free PMC article. - DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
Megiorni F, Camero S, Ceccarelli S, McDowell HP, Mannarino O, Marampon F, Pizer B, Shukla R, Pizzuti A, Marchese C, Clerico A, Dominici C. Megiorni F, et al. Oncotarget. 2016 Nov 29;7(48):79342-79356. doi: 10.18632/oncotarget.12688. Oncotarget. 2016. PMID: 27764816 Free PMC article. - Hypermethylation of death-associated protein (DAP) kinase CpG island is frequent not only in B-cell but also in T- and natural killer (NK)/T-cell malignancies.
Nakatsuka S, Takakuwa T, Tomita Y, Hoshida Y, Nishiu M, Yamaguchi M, Nishii K, Yang WI, Aozasa K. Nakatsuka S, et al. Cancer Sci. 2003 Jan;94(1):87-91. doi: 10.1111/j.1349-7006.2003.tb01357.x. Cancer Sci. 2003. PMID: 12708480 Free PMC article. - Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors.
Ehrlich M, Woods CB, Yu MC, Dubeau L, Yang F, Campan M, Weisenberger DJ, Long T, Youn B, Fiala ES, Laird PW. Ehrlich M, et al. Oncogene. 2006 Apr 27;25(18):2636-45. doi: 10.1038/sj.onc.1209145. Oncogene. 2006. PMID: 16532039 Free PMC article. - Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Ogino S, et al. Neoplasia. 2006 Jun;8(6):458-64. doi: 10.1593/neo.06247. Neoplasia. 2006. PMID: 16820091 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous